• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CSPC Pharmaceutical Group (SEHK:1093), Why Is Its Latest Update Drawing Attention?

    Simply Wall St·10/15/2026 17:28:34
    語音播報

    CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after presenting Phase I data for its Nectin-4 antibody drug SYS6002 in previously treated advanced cervical cancer at IGCS2026.

    Against this clinical backdrop, CSPC Pharmaceutical Group’s shares at HK$8.865 reflect a 9.44% 90 day share price return and a 4.54% year to date share price return, while the 1 year total shareholder return is slightly down 0.73% but the 3 year total shareholder return is up 76.74%. This suggests that longer term momentum has been stronger than the recent pullback.

    Spot emerging oncology stories alongside CSPC Pharmaceutical Group by scanning our hand picked list of 126 healthcare AI stocks.

    Bulls see SYS6002 and a broad drug portfolio as underappreciated growth options, while bears focus on slower net income and oncology risk. Which side do CSPC Pharmaceutical Group’s current valuation markers support next?

    Preferred P/E of 11.6x: Is it justified for CSPC Pharmaceutical Group?

    CSPC Pharmaceutical Group changes hands at a P/E of 11.6x, which screens as inexpensive compared with both peers and the broader Hong Kong pharmaceuticals sector.

    The P/E ratio compares the current share price to earnings per share and gives you a quick read on how much investors are paying for each unit of profit. For a business like CSPC Pharmaceutical Group, which is already profitable and active across finished drugs, bulk products and other healthcare lines, earnings-based measures are a common way investors frame valuation.

    That 11.6x P/E sits well below the Hong Kong pharmaceuticals industry average of 13.6x and even further below the peer group average of 19.5x. It is also beneath an estimated fair P/E of 17.1x that our model suggests the market could move towards if sentiment on earnings and risk normalised. This points to the current pricing being relatively conservative on profit expectations.

    Explore the SWS fair ratio for CSPC Pharmaceutical Group.

    Result: Price-to-earnings of 11.6x (UNDERVALUED)

    Still, revenue growth of 1.27% alongside a 7.66% decline in net income suggests earnings quality questions that could limit how far CSPC Pharmaceutical Group’s P/E can be rerated.

    Find out about the key risks to this CSPC Pharmaceutical Group narrative.

    Another View on CSPC Pharmaceutical Group’s Value

    A different lens comes from our DCF model, which points to a future cash flow value of around HK$14.14 per share versus the current HK$8.87. That suggests CSPC Pharmaceutical Group could be trading at a sizable discount. How much weight do you place on long range cash flow assumptions compared with near term earnings multiples?

    Look into how the SWS DCF model arrives at its fair value.

    1093 Discounted Cash Flow as at Oct 2026
    1093 Discounted Cash Flow as at Oct 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CSPC Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 195 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    If this mix of cautious and optimistic signals around CSPC Pharmaceutical Group feels finely balanced, consider acting promptly, reviewing the data, and weighing the 3 key rewards and 2 important warning signs.

    Looking for more CSPC Pharmaceutical Group style ideas?

    CSPC Pharmaceutical Group may be your starting point, but casting a wider net with focused stock lists gives you more options to test your thesis and timing.

    Use these targeted screens to pressure test your next move on Simply Wall St’s Screener before the crowd chases the same ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.